Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
HIV-1
antiretroviral therapy
drug resistance
integrase
surveillance
Journal
AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
9
3
2021
medline:
6
11
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
There has been no systematic review of the prevalence of transmitted integrase strand transfer inhibitor (INSTI) resistance. We systematically searched the English-language PubMed database and GenBank to identify studies published since 2010 reporting 50 or more INSTI-naive HIV-1-infected adults undergoing integrase genotyping. We extracted data related to country, sample year, specimen type, sequencing method, and subtype. For studies with sequences in GenBank, we determined the prevalence of three categories of INSTI-associated resistance mutations: (1) nonpolymorphic INSTI-selected drug resistance mutations (DRMs) that we refer to as surveillance DRMs; (2) rarely selected nonpolymorphic INSTI-associated DRMs; and (3) common polymorphic accessory INSTI-selected DRMs. A total of 103 studies met inclusion criteria including 75 studies in GenBank containing integrase sequences from 16,481 INSTI-naive persons. The median sample year was 2013 (interquartile range: 2008-2014). The prevalence of INSTI surveillance DRMs, rarely selected DRMs, and common polymorphic accessory INSTI-selected DRMs were 0.5%, 0.8%, and 6.2%, respectively. There was no association between the presence of nonpolymorphic surveillance DRM and region, sample year, or subtype. Two surveillance DRMs, E138K and R263K occurred in 0.15% and 0.10% of naive sequences, respectively. Several lines of evidence suggested that the 0.5% prevalence of surveillance DRMs partly reflects the cumulative natural occurrence of these mutations in the absence of selective drug pressure. There was an unexplained temporal increase in the proportion of sequences with polymorphic accessory mutations. The prevalence of INSTI-associated surveillance DRMs is low even in regions where INSTIs have been a major component of antiretroviral therapy for several years. The presence of INSTI-associated surveillance DRMs in INSTI-naive persons likely results from actual cases of transmitted INSTI resistance and from a low background level reflecting the cumulative rare natural occurrence of several nonpolymorphic mutations.
Identifiants
pubmed: 33683148
doi: 10.1089/AID.2020.0261
pmc: PMC8665799
doi:
Substances chimiques
HIV Integrase Inhibitors
0
HIV Integrase
EC 2.7.7.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
736-743Références
J Antimicrob Chemother. 2020 Nov 1;75(11):3311-3318
pubmed: 32728703
Sci Rep. 2016 Oct 25;6:35779
pubmed: 27779200
Clin Infect Dis. 2019 Jan 7;68(2):177-187
pubmed: 30052811
J Infect Dis. 2016 Aug 1;214(3):399-402
pubmed: 27130429
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182
pubmed: 31617907
Antimicrob Agents Chemother. 2015 Nov 16;60(2):757-65
pubmed: 26574015
AIDS Res Hum Retroviruses. 2019 Feb;35(2):213-216
pubmed: 30229661
Antivir Ther. 2017;22(5):443-446
pubmed: 28076335
Clin Infect Dis. 2017 Oct 15;65(8):1274-1281
pubmed: 28605418
Viruses. 2020 Jun 27;12(7):
pubmed: 32605062
J Virol. 2016 Jun 10;90(13):6058-6070
pubmed: 27099321
AIDS. 2017 Oct 23;31(16):2235-2244
pubmed: 28991024
J Infect Dis. 2021 Mar 3;223(5):866-875
pubmed: 32644119
J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55
pubmed: 20634701
J Virol. 2014 Aug;88(16):9268-76
pubmed: 24899199
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
J Glob Antimicrob Resist. 2020 Mar;20:298-303
pubmed: 31518723
PLoS One. 2009;4(3):e4724
pubmed: 19266092
J Antimicrob Chemother. 2019 Jun 1;74(6):1693-1700
pubmed: 30838386
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785